Skip Navigation

Differentiated Portfolio

We deploy a multidimensional strategy to build up a unique portfolio to enable profitable growth.

With our internal R&D resources and state-of-art manufacturing facilities, we produce and promote an unique portfolio of high quality and difficult-to-make specialty generics in the filed of cardiology, nephrology, central nervous system, women health, and anti-obesity with a primary focus on addressing the fast-growing oncology market. We always keep more than 20 strategically selected projects in development and registrations across Asia and the US and has more than 250 products in the market.

We also continuously invest in diversifying our product portfolio with tail-end brands, biosimilars, NCEs, and over-then-counter (OTC) products via product acquisition or licensing-in partnership with support from external resources.

Enable Profitable Growth

  • 100+
    Development projects
  • 250+
    Marketed products

Committed to Quality

The treatment of millions of patients around the world will depend on the safe and reliable production of medicines. Strong commitment to quality is one of Lotus DNAs, and at Lotus, robust quality control and a reliable supply of medicines to our partners are a cornerstone of our business.


Prescription Drugs

Exceptional teams with proven track records are building a next generation generics company. Our product portfolio consists of a broad range of leading molecules for the treatment for oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity.

Export Oncology

Self-developed Oncology Drugs for Global Markets

We are specialized in oral oncology drugs in form of tablets and hard/softgel capsules in our industry-leading infrastructure with quality manufacturing capabilities certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PDMA, China FDA, and Brazil ANVISA.



We sell and promote certain brand products by product acquisition or licensing-in partnership in the region. Our business model ensures competitive advantage by acquiring or licensing in tail-end brand products for enhanced speed and flexibility.



Through strategic licensing-in partnership, we also offer patients with more affordable biosimilar products.



In addition to prescription drugs, we also provide over-the-counter (OTC) products to empower people to enjoy healthier lives with their unique healthcare needs.


Strong R&D Execution

We continuously to invest in building up differentiated portfolio by leveraging our well-experienced R&D team. We have a strong R&D pipeline for the markets with great potentials worldwide, including the US, APAC, and China.

Risk Management

Drug Risk Management Plan

Lotus strictly implements drug risk management plan for specific products per Taiwan authority’s request and estimates the drug risk management plan periodically to enhance medication safety. (For Taiwan only)